A pragmatic approach to biochemical systems theory applied to an α-synuclein-based model of Parkinson's disease
暂无分享,去创建一个
Robert L. Green | Randolph A. Coleman | R. A. Coleman | Matthew B. Sass | Alyson N. Lorenz | R. Green | M. Sass | Matthew B Sass
[1] P. Molinoff,et al. Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .
[2] J. Luzio,et al. Ubiquitin-dependent sorting of integral membrane proteins for degradation in lysosomes. , 2007, Current opinion in cell biology.
[3] H. Fedorow. Neuromelanin in human dopamine neurons. , 2005 .
[4] E. Bennett,et al. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. , 2005, Molecular cell.
[5] A. Cuervo,et al. Chaperone-mediated autophagy in aging and neurodegeneration: Lessons from α-synuclein , 2007, Experimental Gerontology.
[6] P. Lockhart,et al. Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.
[7] Patrik Brundin,et al. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.
[8] P Riederer,et al. Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.
[9] L. Petrucelli,et al. Co-association of parkin and α-synuclein , 2001 .
[10] E. Junn,et al. Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.
[11] L. Hicke. Ubiquitin‐dependent internalization and down‐regulation of plasma membrane proteins , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] M. Cookson,et al. Cell systems and the toxic mechanism(s) of α-synuclein , 2008, Experimental Neurology.
[13] D. Ecker,et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. , 1989, Science.
[14] P. Riederer,et al. Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. , 2008, Parkinsonism & related disorders.
[15] C. Olanow,et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.
[16] D. Sulzer,et al. α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration , 2006, The Journal of Neuroscience.
[17] D. Fell. Metabolic control analysis: a survey of its theoretical and experimental development. , 1992, The Biochemical journal.
[18] P. Højrup,et al. Proteasomal Inhibition by α-Synuclein Filaments and Oligomers* , 2004, Journal of Biological Chemistry.
[19] Sarah J. Tabrizi,et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .
[20] M. Savageau. Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. , 1969, Journal of theoretical biology.
[21] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[22] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[23] M. Savageau. Biochemical systems analysis. II. The steady-state solutions for an n-pool system using a power-law approximation. , 1969, Journal of theoretical biology.
[24] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[25] Poorvi Kaushik,et al. Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis , 2007, Journal of Computational Neuroscience.
[26] C. Ross,et al. Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.
[27] M. Hallett,et al. Levodopa in the treatment of Parkinson's disease: Current controversies , 2004, Movement disorders : official journal of the Movement Disorder Society.
[28] P. Lansbury,et al. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.
[29] S. Schreiber,et al. Downregulation of free ubiquitin: a novel mechanism of p53 stabilization and neuronal cell death. , 2001, Brain research. Molecular brain research.
[30] D. Rubinsztein. Autophagy Induction Rescues Toxicity Mediated by Proteasome Inhibition , 2007, Neuron.
[31] Shosuke Ito,et al. A Chemist's View of Melanogenesis , 2003 .
[32] Graeme Eisenhofer,et al. Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine , 2004, Pharmacological Reviews.
[33] Jeremy N. Skepper,et al. α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.
[34] J. Bolton,et al. Role of quinones in toxicology. , 2000, Chemical research in toxicology.
[35] A. Matouschek,et al. Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.
[36] H. Ischiropoulos,et al. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? , 2003, The Journal of clinical investigation.
[37] T. Dawson,et al. Parkin-associated Parkinson’s disease , 2004, Cell and Tissue Research.
[38] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[39] A. Ciechanover,et al. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.
[40] D. Sulzer,et al. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease , 2007, Trends in Neurosciences.
[41] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[42] Barry Halliwell,et al. Oxidative stress and neurodegeneration: where are we now? , 2006, Journal of neurochemistry.
[43] P Mendes,et al. Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. , 1997, Trends in biochemical sciences.
[44] M. Farrer,et al. Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .
[45] Juan Carlos Nuño,et al. METATOOL: for studying metabolic networks , 1999, Bioinform..
[46] K. O’Malley,et al. The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.
[47] K D Wilkinson,et al. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. , 1989, Science.
[48] Aaron Ciechanover,et al. The ubiquitin-proteasome proteolytic pathway , 1994, Cell.
[49] F. Gorin,et al. Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson’s disease , 2006, Neuroscience.
[50] Daewoo Lee,et al. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein. , 2007, The European journal of neuroscience.
[51] N. Hattori,et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin‐like domain , 2003, EMBO reports.
[52] E. Masliah,et al. α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .
[53] Stefan Schuster,et al. YANA – a software tool for analyzing flux modes, gene-expression and enzyme activities , 2005, BMC Bioinformatics.
[54] A. Cuervo,et al. Oxidative stress and autophagy. , 2006, Antioxidants & redox signaling.
[55] S. Emr,et al. Receptor downregulation and multivesicular-body sorting , 2002, Nature Reviews Molecular Cell Biology.
[56] M. Zigmond,et al. A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.
[57] P. Blumbergs,et al. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. , 1995, Brain : a journal of neurology.
[58] B. Sommer,et al. Part I: Parkin-associated proteins and Parkinson’s disease , 2003, Neuropharmacology.
[59] P. Højrup,et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. , 2004, The Journal of biological chemistry.
[60] J. Keller,et al. Dopamine induces proteasome inhibition in neural PC12 cell line. , 2000, Free radical biology & medicine.
[61] Nobutaka Hattori,et al. Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.
[62] N. Heintz,et al. Autophagy and Its Possible Roles in Nervous System Diseases, Damage and Repair , 2005, Autophagy.
[63] Andrew B West,et al. Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.
[64] T. Nagatsu. [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.
[65] V. Buchman,et al. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.
[66] Vidya N. Nukala,et al. Characterization of chronic low‐level proteasome inhibition on neural homeostasis , 2003, Journal of neurochemistry.
[67] M. Zigmond,et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[68] Eberhard O. Voit,et al. Computational Systems Analysis of Dopamine Metabolism , 2008, PloS one.
[69] Y. Imai,et al. Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity* , 2000, The Journal of Biological Chemistry.
[70] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[71] L. Pallanck,et al. Parkin A Multipurpose Neuroprotective Agent? , 2003, Neuron.
[72] Mudita Singhal,et al. COPASI - a COmplex PAthway SImulator , 2006, Bioinform..
[73] D. Sulzer,et al. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour , 2001, Molecular pathology : MP.
[74] I. Sora,et al. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[75] T. Dawson,et al. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[76] Eberhard O. Voit,et al. Computational Analysis of Biochemical Systems: A Practical Guide for Biochemists and Molecular Biologists , 2000 .
[77] Linda Hicke,et al. Ubiquitin and proteasomes: Protein regulation by monoubiquitin , 2001, Nature Reviews Molecular Cell Biology.
[78] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[79] S. Lipton,et al. Molecular pathways to neurodegeneration , 2004, Nature Medicine.
[80] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[81] Martin Rechsteiner,et al. Recognition of the polyubiquitin proteolytic signal , 2000, The EMBO journal.
[82] K. Vrana,et al. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.
[83] D. Gray,et al. Damage control – a possible non‐proteolytic role for ubiquitin in limiting neurodegeneration , 2001, Neuropathology and applied neurobiology.
[84] B. Bergamasco,et al. Modifications of the iron–neuromelanin system in Parkinson's disease , 2006, Journal of neurochemistry.
[85] Mark R Cookson,et al. The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.
[86] C. Ross,et al. Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.
[87] A. Ciechanover,et al. The ubiquitin system. , 1998, Annual review of biochemistry.
[88] C. Olanow,et al. Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.
[89] Aaron Ciechanover,et al. The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.
[90] Nancy A. Jenkins,et al. Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[91] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[92] D. Selkoe,et al. Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.
[93] MoonHee Lee,et al. Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .
[94] L. Greene,et al. Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.
[95] J. Dice,et al. Mechanisms of chaperone-mediated autophagy. , 2004, The international journal of biochemistry & cell biology.
[96] Li Chen,et al. α-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains* , 2005, Journal of Biological Chemistry.
[97] M. Savageau. Biochemical systems analysis. III. Dynamic solutions using a power-law approximation , 1970 .